Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Induced by Imatinib

被引:5
作者
Zgolli, F. [1 ,2 ]
Aouinti, I [1 ,2 ]
Charfi, O. [1 ,2 ]
Badri, T. [2 ,3 ]
Elaidli, S. [1 ,2 ]
Kastalli, S. [1 ,2 ]
Lakhoua, G. [1 ,2 ]
Zaiem, A. [1 ,2 ]
机构
[1] Natl Ctr Chalbi Belkahia Pharmacovigilance, 9 Ave Dr Zouhaier Essafi, Tunis 1006, Tunisia
[2] Univ Tunis El Manar, Fac Med, Res Unit UR17ES12, 15 Rue Djebel Lakhdhar, Tunis 1007, Tunisia
[3] Habib Thameur Hosp, Dept Dermatol, Tunis, Tunisia
关键词
Drug hypersensitivity syndrome; DRESS syndrome imatinib; pharmacovigilance; adverse drug reaction; CML; GIST;
D O I
10.2174/1574886314666190130150243
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Imatinib is the treatment of choice in patients with locally advanced or metastatic gastrointestinal stromal tumours (GIST). Clinical tolerance of imatinib is excellent except for the common adverse drug reaction (ADR). Drug rash with eosinophilia and systemic symptoms (DRESS syndrome) is a severe, potentially life-threatening drug-induced hypersensitivity reaction, characterized by cutaneous eruptions, fever, diffuse lymphadenopathy, along with eosinophilia, and elevated liver function tests. This ADR is rarely reported with imatinib. Only four cases of DRESS syndrome associated with imatinib have already been published. Case Report: We report an exceptional case of DRESS syndrome associated with imatinib in a 46 year-old woman with GIST. Two weeks after she had started imatinib therapy, she developed a skin rash, with eosinophilia and elevated liver tests. Plasma level of imatinib was within the therapeutic range. Imatinib was immediately discontinued. A favourable outcome was slowly observed after the drug had been stopped. Results and Conclusion: This case was scored three according to the European Registry of Severe Cutaneous Adverse Reactions Study Group (RegiSCAR). The Naranjo score for imatinib was five (probable).
引用
收藏
页码:151 / 154
页数:4
相关论文
共 10 条
  • [1] DRESS syndrome
    Descamps, Vincent
    Ranger-Rogez, Sylvie
    [J]. JOINT BONE SPINE, 2014, 81 (01) : 15 - 21
  • [2] Din Omar S, 2008, Ther Clin Risk Manag, V4, P149
  • [3] Fregert S., 1981, MANUAL CONTACT DERMA, V2, P71
  • [4] Imatinib-induced DRESS
    Goldman, J.
    Duval-Modeste, A. -B.
    Lambert, A.
    Contentin, N.
    Courville, P.
    Musette, P.
    Joly, P.
    [J]. ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2008, 135 (05): : 393 - 396
  • [5] Indications for imatinib mesylate therapy and clinical management
    Guilhot, F
    [J]. ONCOLOGIST, 2004, 9 (03) : 271 - 281
  • [6] Kumar Meet, 2014, Indian Dermatol Online J, V5, pS120, DOI 10.4103/2229-5178.146189
  • [7] A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG-REACTIONS
    NARANJO, CA
    BUSTO, U
    SELLERS, EM
    SANDOR, P
    RUIZ, I
    ROBERTS, EA
    JANECEK, E
    DOMECQ, C
    GREENBLATT, DJ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (02) : 239 - 245
  • [8] A new case of imatinib-induced drug reaction with eosinophilia and systemic symptoms
    Saidi, Wafa
    Lahouel, Ines
    Laarif, Molka
    Aounallah, Amina
    [J]. INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2017, 83 (02) : 224 - +
  • [9] Sweetman S.C., Martindale: The Complete Drug Reference
  • [10] Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by imatinib in chronic myeloid leukemia
    Vatel, Orlane
    Aumont, Cedric
    Mathy, Vincent
    Petit, Morgane
    Feriel, Joffrey
    Sloma, Ivan
    Bennaceur-Griscelli, Annelise
    Turhan, Ali G.
    [J]. LEUKEMIA & LYMPHOMA, 2017, 58 (02) : 473 - 474